Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 41

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Thalassaemia beta+2

Not yet recruiting

Phase 3 study of mitapivat for effectiveness and safety in children with non‑transfusion‑dependent alpha or beta thalassemia

Investigational
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Thalassaemia beta+2

Not yet recruiting

Phase 3 Study of Mitapivat to Reduce Transfusions in Children with Alpha or Beta Transfusion‑Dependent Thalassemia

Investigational
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Acute myeloid leukaemia

Not yet recruiting

Fludarabine with drug combination for older or frail patients with acute myeloid leukemia undergoing haploidentical stem cell transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Institut Paoli-Calmettes

Autoimmune haemolytic anaemia+3

Not yet recruiting

Study of cc-97540 CD19‑Targeted NEX‑T CAR T in participants with chronic immune thrombocytopenia and autoimmune hemolytic anemia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Cutaneous T-cell lymphoma

Not yet recruiting

Topical delgocitinib safety study in patients with cutaneous T‑cell lymphoma (mycosis fungoides)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Region Midtjylland

Acute myeloid leukaemia+1

Not yet recruiting

Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Fondazione IRCCS San Gerardo Dei Tintori

Plasma cell myeloma

Not yet recruiting

Teclistamab drug combination versus daratumumab and lenalidomide in MRD‑positive multiple myeloma patients after stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

B precursor type acute leukaemia

Not yet recruiting

Phase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
  • Sponsor:Goethe University Frankfurt

Plasma cell myeloma

Not yet recruiting

Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Polish Myeloma Consortium

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Acute lymphocytic leukaemia+1

Not yet recruiting

Brain Fluid Clearance Guided Intrathecal Chemotherapy with Gadobutrol in Adolescents aged 12-17 with Acute Lymphoblastic Leukemia and Lymphoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Gadobutrol
  • Sponsor:Oslo University Hospital HF

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.